Clinical effect of Gemcitabine combined with Paclitaxel in the treatment of lung cancer patients
GU Guang-en1 CHEN Wei-yun2 ZHONG Li-lan3
1.Dispensary for Western Medicine, Foshan Hospital of Traditional Chinese Medicine, Guangdong Province, Foshan 528000, China;
2.Department of Pulmonary Disease, Foshan Hospital of Traditional Chinese Medicine, Guangdong Province, Foshan 528000, China;
3.Department of Ultrasound, Foshan Hospital of Traditional Chinese Medicine,Guangdong Province, Foshan 528000, China
Abstract：Objective To investigate and analyze the clinical effect of Gemcitabine combined with Paclitaxel in patients with lung cancer.Methods Ninety-two patients with lung cancer admitted to our hospital from March 2017 to March 2018 were selected as the study subjects.They were divided into control group (46 cases) and study group (46 cases)according to random number table method.The control group was treated with Gemcitabine combined with Cisplatin,and the study group was treated with Gemcitabine combined with Paclitaxel.The total effective rate, pulmonary function and adverse reactions were compared between the two groups.Results The total effective rate of the study group was higher than that of the control group, the difference was statistically significant (P<0.05).There was no significant difference in lung function indexes such as forced expiratory volume in 1 s (FEV1), FEV1 percentage (FEV1%) and the ratio of FEV1 to forced vital capacity (FVC) (FEV1/FVC) between the two groups before treatment (P>0.05).After treatment, the above lung function indexes of the two groups were higher than those before treatment, and the study group was significantly higher than the control group, with statistically significant difference (P<0.05).After treatment, the incidence of liver function damage, alopecia, bone marrow suppression, peripheral neurotoxicity and the total incidence of adverse reaction in the study group were significantly lower than those in the control group (P<0.05).Conclusion Gemcitabine combined with Paclitaxel in the treatment of lung cancer has significant therapeutic effect, less impact on pulmonary function, and low incidence of adverse reactions, which is worthy of promotion.
京公网安备 11010502046607号